巣状分節性糸球体硬化症治療薬の世界市場レポート 2025年

巣状分節性糸球体硬化症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.8%で、248億7,000万米ドルに成長します。予測期間の成長は、研究開発費、ヘルスケア支出の増加、意識と診断の高まり、高齢化、政府の取り組み、資金調達に起因すると考えられます。予測期間における主な動向としては、創薬研究開発における技術進歩、臨床試験パイプラインの拡大、治療に対する償還の改善、企業の研究施設の拡大などが挙げられます。

腎感染症の罹患率の増加は、近い将来、巣状分節性糸球体硬化症（FSGS）治療薬市場の拡大を牽引する見通しです。腎臓感染症は、腎盂腎炎としても知られ、片方または両方の腎臓を侵す尿路感染症（UTI）の重症型です。腎疾患の治療用に開発された巣状分節性糸球体硬化症（FSGS）治療薬は、病状を管理し腎機能を高める上で多くの利点を提供します。蛋白尿を減少させ、腎障害の進行を遅らせ、最終的には腎臓病を患う患者のQOLを改善することでこれを達成します。例えば、2022年7月現在、米国保健福祉省の一部門である疾病対策予防センターのデータによると、米国人口の約15％、3700万人が腎臓病に罹患していることが明らかになりました。2021年には、45～64歳で12％、18～44歳で6％の有病率でした。その結果、腎臓感染症の増加が巣状分節性糸球体硬化症（FSGS）市場成長の原動力となっています。

ヘルスケア支出の増加は、今後数年間における巣状分節性糸球体硬化症（FSGS）治療薬市場の成長を促進すると予想されます。ヘルスケア支出とは、特定のヘルスケアシステムや経済圏において、定められた期間内にヘルスケアサービスや関連商品、活動に割り当てられる総資金を指します。ヘルスケア支出の増加は、巣状分節性糸球体硬化症（FSGS）治療薬の開発と利用可能性に大きな利益をもたらす可能性があり、研究資金を強化し、臨床試験を促進し、最終的に医薬品生産を改善するためです。例えば、2023年11月、カナダを拠点とする団体であるCanadian Institute for Health Informationは、カナダにおける総医療費は2023年に3,440億米ドルに達すると予測され、これは一人当たり8,740米ドルに相当すると報告しています。これは、2022年の医療費が1.5％の伸びにとどまった前年と比較すると2.8％増となり、ヘルスケア投資の回復が顕著であることを浮き彫りにしています。したがって、医療費の増加が巣状分節性糸球体硬化症（FSGS）治療薬市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界巣状分節性糸球体硬化症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の巣状分節性糸球体硬化症治療薬市場：成長率分析
• 世界の巣状分節性糸球体硬化症治療薬市場の実績：規模と成長, 2019-2024
• 世界の巣状分節性糸球体硬化症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界巣状分節性糸球体硬化症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の巣状分節性糸球体硬化症治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロスマピモド
• SHP-627
• スパルセンタン
• TM-5484
• その他のタイプ
• 世界の巣状分節性糸球体硬化症治療薬市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 免疫抑制薬
• アンジオテンシン変換酵素（ACE）阻害剤
• A.R.ブロッカー
• 利尿剤
• その他の治療法
• 世界の巣状分節性糸球体硬化症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の巣状分節性糸球体硬化症治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー

第7章 地域別・国別分析

• 世界の巣状分節性糸球体硬化症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の巣状分節性糸球体硬化症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 巣状分節性糸球体硬化症治療薬市場：競合情勢
• 巣状分節性糸球体硬化症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca Plc
• Fresenius Kabi Ltd.
• GSK Plc
• Medtronic Plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Astellas Pharma Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Mylan N.V.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Alexion Pharmaceuticals
• Wockhardt

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 巣状分節性糸球体硬化症治療薬市場2029：新たな機会を提供する国
• 巣状分節性糸球体硬化症治療薬市場2029：新たな機会を提供するセグメント
• 巣状分節性糸球体硬化症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease characterized by the development of scar tissue in the filters of the kidneys. Medications designed to treat and manage the progression of FSGS are referred to as focal segmental glomerulosclerosis drugs.

The primary focal segmental glomerulosclerosis drugs include losmapimod, SHP-627, sparsentan, tm-5484, and others. Losmapimod is an investigational drug belonging to the class of p38 mitogen-activated protein kinase (MAPK) inhibitors. Treatment options encompass corticosteroids, immunosuppressive drugs, ACE inhibitors, AR blockers, diuretics, and more, which can be administered through various routes, including oral and parenteral. These medications serve various end-users, such as hospitals, homecare services, specialty clinics, and more.

The focal segmental glomerulosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides focal segmental glomerulosclerosis drugs market statistics, including focal segmental glomerulosclerosis drugs industry global market size, regional shares, competitors with a focal segmental glomerulosclerosis drugs market share, detailed focal segmental glomerulosclerosis drugs market segments, market trends and opportunities and any further data you may need to thrive in the focal segmental glomerulosclerosis drugs industry. This focal segmental glomerulosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The focal segmental glomerulosclerosis drugs market size has grown strongly in recent years. It will grow from $15.77 billion in 2024 to $17.08 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing disease prevalence, growing demand for new treatments, growing interest from pharmaceutical sector, increasing government support.

The focal segmental glomerulosclerosis drugs market size is expected to see strong growth in the next few years. It will grow to $24.87 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to research and development expenditure, rising healthcare expenditure, growing awareness and diagnosis, aging population, government initiatives and funding. Major trends in the forecast period include technological advancements in drug discovery and development, expanding clinical trials pipeline, improved reimbursement for focal segmental glomerulosclerosis drugs treatments, expansion of corporate research facilities.

The increasing incidence of kidney infections is poised to drive the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market in the foreseeable future. Kidney infections, also known as pyelonephritis, represent a severe form of urinary tract infection (UTI) that affects one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, designed for the treatment of kidney diseases, offer numerous advantages in managing the condition and enhancing kidney function. They achieve this by reducing proteinuria, slowing the progression of kidney damage, and ultimately improving the quality of life for patients suffering from kidney diseases. For example, as of July 2022, data from the Centers for Disease Control and Prevention, a division of the US Department of Health and Human Services, revealed that approximately 15% of the US population, equivalent to 37 million individuals, were afflicted by kidney disease. In 2021, the prevalence was 12% among individuals aged 45-64 and 6% among those between 18 and 44. Consequently, the increasing occurrence of kidney infections serves as a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) market.

The increasing healthcare expenditure is expected to drive the growth of the focal segmental glomerulosclerosis (FSGS) drugs market in the coming years. Healthcare expenditure refers to the total funds allocated for healthcare services and related goods and activities within a specific healthcare system or economy over a defined timeframe. Higher healthcare expenditures can significantly benefit the development and availability of drugs for focal segmental glomerulosclerosis (FSGS), as they enhance research funding and facilitate clinical trials, ultimately improving drug production. For example, in November 2023, the Canadian Institute for Health Information, a Canada-based organization, reported that total health spending in Canada is projected to reach $344 billion in 2023, which equates to $8,740 per person. This represents a 2.8% increase compared to the previous year, which experienced a growth of only 1.5% in health spending in 2022, highlighting a notable recovery in healthcare investment. Therefore, the rise in healthcare expenditures is a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) drugs market.

Prominent companies in the focal segmental glomerulosclerosis (FSGS) market are increasingly directing their efforts toward product development and innovation to deliver dependable solutions to their clientele and bolster their market standing. As an example, in February 2023, Travere Therapeutics, a biopharmaceutical firm headquartered in the United States, introduced FILSPARI for focal segmental glomerulosclerosis (FSGS), an FDA-approved oral medication. FILSPARI is designed to treat IgA nephropathy (IgAN) and represents the first non-immunosuppressive therapy aimed at reducing proteinuria in IgAN, a rare kidney disease. Furthermore, FILSPARI has received orphan drug designation in both the United States and Europe for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).

In October 2023, Amgen, a biotechnology company based in the U.S., completed the acquisition of Horizon Therapeutics plc for $27.8 billion. This acquisition aims to enhance Amgen's product portfolio, which includes essential medications such as Tepezza and Krystexxa, utilized in the treatment of rare inflammatory conditions. Horizon Therapeutics is also a U.S.-based biotechnology company specializing in drugs for focal segmental glomerulosclerosis.

Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.

North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The focal segmental glomerulosclerosis (FSGS) drugs market consists of sales of rituximab, statins, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on focal segmental glomerulosclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for focal segmental glomerulosclerosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The focal segmental glomerulosclerosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Losmapimod; SHP-627; Sparsentan; TM-5484; Other Types
• 2) By Treatment: Corticosteroids; Immunosuppressive Drugs; Angiotensin Converting Enzymes (ACE) Inhibitors; A.R. Blockers; Diuretics; Other Treatments
• 3) By Route of Administration: Oral; Parenteral
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Focal Segmental Glomerulosclerosis Drugs Market Characteristics

3. Focal Segmental Glomerulosclerosis Drugs Market Trends And Strategies

4. Focal Segmental Glomerulosclerosis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Focal Segmental Glomerulosclerosis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Focal Segmental Glomerulosclerosis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Focal Segmental Glomerulosclerosis Drugs Market Growth Rate Analysis
• 5.4. Global Focal Segmental Glomerulosclerosis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Focal Segmental Glomerulosclerosis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Focal Segmental Glomerulosclerosis Drugs Total Addressable Market (TAM)

6. Focal Segmental Glomerulosclerosis Drugs Market Segmentation

• 6.1. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Losmapimod
• SHP-627
• Sparsentan
• TM-5484
• Other Types
• 6.2. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Drugs
• Angiotensin Converting Enzymes (ACE) Inhibitors
• A.R. Blockers
• Diuretics
• Other Treatments
• 6.3. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users

7. Focal Segmental Glomerulosclerosis Drugs Market Regional And Country Analysis

• 7.1. Global Focal Segmental Glomerulosclerosis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Focal Segmental Glomerulosclerosis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market

• 8.1. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Focal Segmental Glomerulosclerosis Drugs Market

• 9.1. China Focal Segmental Glomerulosclerosis Drugs Market Overview
• 9.2. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Focal Segmental Glomerulosclerosis Drugs Market

• 10.1. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Focal Segmental Glomerulosclerosis Drugs Market

• 11.1. Japan Focal Segmental Glomerulosclerosis Drugs Market Overview
• 11.2. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Focal Segmental Glomerulosclerosis Drugs Market

• 12.1. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Focal Segmental Glomerulosclerosis Drugs Market

• 13.1. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Focal Segmental Glomerulosclerosis Drugs Market

• 14.1. South Korea Focal Segmental Glomerulosclerosis Drugs Market Overview
• 14.2. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Focal Segmental Glomerulosclerosis Drugs Market

• 15.1. Western Europe Focal Segmental Glomerulosclerosis Drugs Market Overview
• 15.2. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Focal Segmental Glomerulosclerosis Drugs Market

• 16.1. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Focal Segmental Glomerulosclerosis Drugs Market

• 17.1. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Focal Segmental Glomerulosclerosis Drugs Market

• 18.1. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Focal Segmental Glomerulosclerosis Drugs Market

• 19.1. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Focal Segmental Glomerulosclerosis Drugs Market

• 20.1. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market

• 21.1. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market Overview
• 21.2. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Focal Segmental Glomerulosclerosis Drugs Market

• 22.1. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Focal Segmental Glomerulosclerosis Drugs Market

• 23.1. North America Focal Segmental Glomerulosclerosis Drugs Market Overview
• 23.2. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Focal Segmental Glomerulosclerosis Drugs Market

• 24.1. USA Focal Segmental Glomerulosclerosis Drugs Market Overview
• 24.2. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Focal Segmental Glomerulosclerosis Drugs Market

• 25.1. Canada Focal Segmental Glomerulosclerosis Drugs Market Overview
• 25.2. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Focal Segmental Glomerulosclerosis Drugs Market

• 26.1. South America Focal Segmental Glomerulosclerosis Drugs Market Overview
• 26.2. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Focal Segmental Glomerulosclerosis Drugs Market

• 27.1. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Focal Segmental Glomerulosclerosis Drugs Market

• 28.1. Middle East Focal Segmental Glomerulosclerosis Drugs Market Overview
• 28.2. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Focal Segmental Glomerulosclerosis Drugs Market

• 29.1. Africa Focal Segmental Glomerulosclerosis Drugs Market Overview
• 29.2. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Focal Segmental Glomerulosclerosis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Focal Segmental Glomerulosclerosis Drugs Market Competitive Landscape
• 30.2. Focal Segmental Glomerulosclerosis Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Focal Segmental Glomerulosclerosis Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol Myers Squibb Company
• 31.3. AstraZeneca Plc
• 31.4. Fresenius Kabi Ltd.
• 31.5. GSK Plc
• 31.6. Medtronic Plc.
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Astellas Pharma Inc.
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Mylan N.V.
• 31.12. B. Braun Melsungen AG
• 31.13. Hikma Pharmaceuticals PLC
• 31.14. Alexion Pharmaceuticals
• 31.15. Wockhardt

32. Global Focal Segmental Glomerulosclerosis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Focal Segmental Glomerulosclerosis Drugs Market

34. Recent Developments In The Focal Segmental Glomerulosclerosis Drugs Market

35. Focal Segmental Glomerulosclerosis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Focal Segmental Glomerulosclerosis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Focal Segmental Glomerulosclerosis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Focal Segmental Glomerulosclerosis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer